{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=H1+Receptor+Antagonist&page=2", "query": { "intervention": "H1 Receptor Antagonist", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 98, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=H1+Receptor+Antagonist&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=H1+Receptor+Antagonist&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T10:33:10.286Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03436797", "title": "A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Urticaria" ], "interventions": [ { "name": "AK002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allakos Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 47, "start_date": "2018-01-23", "completion_date": "2020-04-06", "has_results": true, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-10-01T10:33:10.286Z", "location_count": 2, "location_summary": "Edgewater, Florida • Cincinnati, Ohio", "locations": [ { "city": "Edgewater", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03436797" }, { "nct_id": "NCT04612803", "title": "Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Irritable Bowel Syndrome", "Dermatographism", "Post-prandial Diarrhea" ], "interventions": [ { "name": "Antihistamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-02-01", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-01T10:33:10.286Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04612803" }, { "nct_id": "NCT06780111", "title": "Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "I-DXd", "type": "BIOLOGICAL" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Rescue Medication", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 298, "start_date": "2025-07-30", "completion_date": "2032-01-04", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-01T10:33:10.286Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06780111" }, { "nct_id": "NCT05795153", "title": "A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "LOU064", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 144, "start_date": "2023-04-05", "completion_date": "2024-04-25", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-10-01T10:33:10.286Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • Aventura, Florida • Greenacres City, Florida + 7 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Aventura", "state": "Florida" }, { "city": "Greenacres City", "state": "Florida" }, { "city": "Boise", "state": "Idaho" }, { "city": "Glenview", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05795153" }, { "nct_id": "NCT07109817", "title": "Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Peripheral Neuropathy" ], "interventions": [ { "name": "Desloratodine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2026-09", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-01T10:33:10.286Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07109817" }, { "nct_id": "NCT02613910", "title": "Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pemphigus" ], "interventions": [ { "name": "Ofatumumab", "type": "DRUG" }, { "name": "Acetaminophen/paracetamol", "type": "DRUG" }, { "name": "Antihistamine (cetirizine or equivalent)", "type": "DRUG" }, { "name": "Prednisone/Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1, "start_date": "2015-12-23", "completion_date": "2016-03-23", "has_results": true, "last_update_posted_date": "2017-06-14", "last_synced_at": "2026-10-01T10:33:10.286Z", "location_count": 2, "location_summary": "Los Angeles, California • Ann Arbor, Michigan", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02613910" }, { "nct_id": "NCT06393374", "title": "Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple-Negative Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1530, "start_date": "2024-06-24", "completion_date": "2037-12-14", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-01T10:33:10.286Z", "location_count": 93, "location_summary": "Mobile, Alabama • Chandler, Arizona • Fountain Valley, California + 78 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06393374" }, { "nct_id": "NCT01661777", "title": "Refractory Eustachian Tube Dysfunction: Are the Symptoms Related to Endolymphatic Hydrops", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Eustachian Tube Dysfunction", "Endolymphatic Hydrops" ], "interventions": [ { "name": "Nasal steroid", "type": "DRUG" }, { "name": "Myringotomy tube placement", "type": "PROCEDURE" }, { "name": "Diuretic", "type": "DRUG" }, { "name": "Antihistamine", "type": "DRUG" }, { "name": "Low salt diet", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BEHAVIORAL" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2012-08", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2014-05-29", "last_synced_at": "2026-10-01T10:33:10.286Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01661777" }, { "nct_id": "NCT04548999", "title": "A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Antihistamine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 769, "start_date": "2020-12-03", "completion_date": "2027-09-08", "has_results": true, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-01T10:33:10.286Z", "location_count": 24, "location_summary": "Homewood, Alabama • Phoenix, Arizona • Irvine, California + 21 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04548999" }, { "nct_id": "NCT07216703", "title": "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sacituzumab Tirumotecan", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Rescue Medications", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1023, "start_date": "2026-01-19", "completion_date": "2031-10-29", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-01T10:33:10.286Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Irvine, California • Orange, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07216703" } ] }